Company intelligence / Profile preview

Vastora

Seoul, Seoul, South Koreadnb.com ↗

Ownership: Private
Development stage: Other

Overview

VasThera has developed a novel class of small molecules that mimic peroxiredoxin enzymatic activity, aiming to restore redox balance in vascular and other chronic diseases. Their lead candidate, VTA‑04, is positioned as a first-in-class disease-modifying therapy for pulmonary arterial hypertension. The company’s approach addresses high unmet needs by targeting underlying pathophysiology rather than just symptoms. Clinical results are not yet available; programs are preclinical or approaching IND submission.

Therapeutic areas: OncologyCardiovascularNeurology
Modalities: Small moleculeSynthetic therapeuticsEnzyme mimetic (Prx nanozyme)
Industry: Biotech

Partnerships

null (no major pharma partnerships publicly disclosed as of latest reports)

Beyond the preview

Go deeper on Vastora.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vastora.

Explore the full profile